Tag: Exact Sciences

All

Abbott to Acquire Exact Sciences in $21 Billion Agreement

The deal positions Abbott to enter the US cancer screening and precision oncology diagnostics market with products including Cologuard and Oncotype DX tests.

Blood Test Shows Superior Sensitivity for Early-Stage Liver Cancer Detection
FDA Approves Exact Sciences’ Non-Invasive Test for Colorectal Cancer Screening
Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection Study
Oncoguard Esophagus Test Achieves High Sensitivity, Specificity
Next-Gen Cologuard Test Demonstrates High Sensitivity, Specificity
Long-Term Study Validates Genomic Assay for Prostate Cancer
Phillips-Medisize, Exact Sciences Collaborate to Fight Colorectal Cancer
Oncoguard Liver Liquid Biopsy Test Shows Potential For Better Early-stage Cancer Detection
Oncotype DX Test Can Spare Chemotherapy for Women with Certain Breast Cancers

All

Oncotype DX Breast Recurrence Score Test Shapes Clinical Practice

New data highlight the role of the test in further individualizing treatment decisions in early breast cancer.

Oncotype Map Pan-Cancer Tissue Test to Guide Treatment for Advanced Cancer
Oncotype Dx GPS Can Guide Treatment for UFI-Risk Prostate Cancer
Real-World Studies Support Utility of Oncotype Dx to Guide Chemotherapy Treatment for Breast Cancer
Exact Sciences Opens New Laboratory to Increase Cologuard Processing Capacity
Noninvasive Test Shown to Increase Colorectal Cancer Screening Compliance
The Cologuard Process

All

Developing and Marketing an FDA-Regulated Test

Exact Sciences overcame significant obstacles to bring cancer screening innovation to patients.

FDA Approves Exact Sciences’ Cologuard Cancer Screening Test

Tag: Exact Sciences

All

Abbott to Acquire Exact Sciences in $21 Billion Agreement

Blood Test Shows Superior Sensitivity for Early-Stage Liver Cancer Detection

FDA Approves Exact Sciences’ Non-Invasive Test for Colorectal Cancer Screening

Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection Study

Oncoguard Esophagus Test Achieves High Sensitivity, Specificity

Next-Gen Cologuard Test Demonstrates High Sensitivity, Specificity

Long-Term Study Validates Genomic Assay for Prostate Cancer

Phillips-Medisize, Exact Sciences Collaborate to Fight Colorectal Cancer

Oncoguard Liver Liquid Biopsy Test Shows Potential For Better Early-stage Cancer Detection

Oncotype DX Test Can Spare Chemotherapy for Women with Certain Breast Cancers

All

Oncotype DX Breast Recurrence Score Test Shapes Clinical Practice

Oncotype Map Pan-Cancer Tissue Test to Guide Treatment for Advanced Cancer

Oncotype Dx GPS Can Guide Treatment for UFI-Risk Prostate Cancer

Real-World Studies Support Utility of Oncotype Dx to Guide Chemotherapy Treatment for Breast Cancer

Exact Sciences Opens New Laboratory to Increase Cologuard Processing Capacity

Noninvasive Test Shown to Increase Colorectal Cancer Screening Compliance

The Cologuard Process

All

Developing and Marketing an FDA-Regulated Test

FDA Approves Exact Sciences’ Cologuard Cancer Screening Test

Sorry, No Posts Found

Clinical Lab Products

Our Parent Company

Key Resources

Helpful Links